Milliseconds Matter: AI Accelerated Stroke Detection, Dr. Chris Mansi, CEO @Viz.AI

HLTH Forward Podcast

In this episode, I am in conversation with Viz.AI CEO, Dr. Chris Mansi, a pioneer in leveraging artificial intelligence for early disease detection. Our discourse unveiled the revolutionary strides Viz.ai has made in the medical field, particularly in neurovascular and cardiology domains. Dr. Mansi elucidated how their AI-powered platform has dramatically reduced time-to-treatment for stroke patients, citing their flagship product that can detect large vessel occlusions in CT scans within minutes, enabling rapid triage and intervention.

Their AI algorithms have shown remarkable efficacy in detecting pulmonary embolisms and aortic dissections, conditions where timely diagnosis can mean the difference between life and death. Dr. Mansi shared a poignant case study where their AI platform identified a subtle aortic abnormality that human radiologists had initially overlooked, potentially averting a catastrophic outcome.

In the United States alone, it's estimated that diagnostic errors contribute to 40,000 to 80,000 deaths annually. Furthermore, approximately 12 million adults annually experience diagnostic errors in outpatient settings.
Chris emphasized that their AI tools are not meant to replace human expertise but to augment it, creating a synergy that promises to revolutionize patient outcomes. By providing rapid, accurate medical imaging analyses, Viz.aAI's technology empowers healthcare providers to make swift, informed decisions, potentially saving thousands of lives each year. This harmonious blend of artificial intelligence and human insight represents a new frontier in medicine, where the early detection of diseases becomes a possibility and a standard of care.

About
Viz.ai, Inc. is emerging as the leader in applied artificial intelligence in healthcare. Our mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. Our flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat. In February 2018, the U.S. Food and Drug Administration (FDA) granted a de novo clearance for Viz LVO, the first-ever computer-aided triage and notification platform. Most recently, Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral image analysis.

Support the show